Find your PDFs fast.
Welcome to the Pubget Medical Subject Headings (MESH) browser. Click on a topic or subtopic below to explore related papers. In the gold box is the most recent paper about the current MESH term, and below are 20 related papers.
Sclerotherapy (0):
Recent article
Sclerotherapy
Abstract
Extrahepatic portal venous obstruction (EHPVO) is the commonest cause of portal hypertension and variceal bleeding in children. Though mortality related to variceal bleeding is uncommon, morbidity due to massive splenomegaly with hypersplenism, growth failure, ectopic varices like rectal varices and...
|
PMID: 21922871
PDF is available here.
PDF is available here.
| < More recent | Older article > |
Abstract
Hepatology (52)6 2010
Abstract
Abstract
To study the management and outcome of children with extrahepatic portal vein obstruction (EHPVO) in a whole country population.
A nationwide multicenter retrospective case series of children with EHPVO was conducted. Data on demographics, radiographic studies, laboratory workup, endoscopic and surg...
|
PMID: 20954284
PDF is available here.
PDF is available here.
Andrologia (42)5 2010
Abstract
Our prediction was that, if genetic problems are excluded, SCO may be the final stage of longstanding hypoxia which deteriorates sperm production in a progressive process over time. This would indicate that SCO is not always an independent disease entity, but may represent deterioration of the testi...
|
PMID: 20860630
PDF is available here.
PDF is available here.
Nippon Shokakibyo Gakkai Zasshi (107)10 2010
Abstract
Klinichna khirurhiia / Ministerstvo okhorony zdorov'ia Ukrainy, Naukove tovarystvo khirurhiv Ukrainy ()9 2010
Abstract
The method of intraoperative sclerotherapy, using 40% glucose solution, for varicocele surgical treatment was proposed. Diathermocoagulation of all visible accompanying veins was conducted for reduction of the varicocele recurrence rate. The recurrence is reduced to 6.6%.
|
PMID: 21090361
PDF is available here.
PDF is available here.
Abstract
Gastroesophageal variceal hemorrhage is a major complication of portal hypertension in 50% to 60% of patients with liver cirrhosis and is a frequent cause of mortality in these patients. The prevalence of variceal hemorrhage is approximately 5% to 15% yearly, and early variceal rebleeding has a rate...
|
PMID: 20691388
PDF is available here.
PDF is available here.
Abstract
Foam sclerotherapy using CO(2)/O(2) foam was well tolerated by patients and resulted in fewer side effects than similar treatment using air foams.
Copyright 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved....
|
PMID: 20547080
PDF is available here.
PDF is available here.
Abstract
These data suggest that compliance with post-procedure compression hosiery and gender are important factors associated with a successful outcome and reported complications following UGFS, respectively.
Copyright 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reser...
|
PMID: 20547076
PDF is available here.
PDF is available here.
Abstract
The combination of endoscopic band ligation (EBL) with either endoscopic injection sclerotherapy (EIS) or thermal therapy has been shown to reduce recurrence of esophageal varices compared to EBL alone. The aim of this prospective trial was twofold: 1) to evaluate the safety and effi...
|
PMID: 19802519
PDF is available here.
PDF is available here.
Urologia Internationalis (85)1 2010
Abstract
We recommend the 3-instillation regimen in patients with chyluria refractory to conservative treatment.
Copyright (c) 2010 S. Karger AG, Basel....
|
PMID: 20224262
PDF is available here.
PDF is available here.
Abstract
The duration of follow-up was a mean of 8 months (range, 3 to 22). Of the 60 patients, 22 were treated once and 38 were treated 2 to 18 times (mean 2.6 times/patient). The mean total volume of ethanol in 60 patients was 11.2 mL (range, 0.5 to 230 mL). Of the 60 patients, 56 had complete volume reduc...
|
PMID: 19962811
PDF is available here.
PDF is available here.
Dermatologic Surgery (36)7 2010
Abstract
Dermatologic Surgery (36)7 2010
Abstract
The efficacy of EO was evaluated in 21 patients (16 pyogenic granulomas and 5 venous lakes). The diameters of the lesions ranged from 0.3 to 1.0 cm. The mean number of EO injections was 1.6 (range 1-4). A CR was achieved in 95% of the reactive vascular lesions (20 CR, 1 MI). Two episodes of transien...
|
PMID: 20533938
PDF is available here.
PDF is available here.
Abstract
Fine needle aspiration alone has been used as a treatment for bronchogenic cysts, but is subject to a high rate of recurrence. The purpose of this study was to review our experience with computed tomography (CT)-guided percutaneous large-needle aspiration and bleomycin sclerotherapy of bronchogenic...
|
PMID: 20537555
PDF is available here.
PDF is available here.
Abstract
Abstract
This is the first randomised clinical trial of ultrasound-guided foam sclerotherapy which is a 3-year follow-up and shows equivalent efficacy of 1% and 3% sclerosant foam. Clinical trial registration number: 2006-07-05.
Copyright (c) 2010 European Society for Vascular Surgery. Published by Elsevier...
|
PMID: 20206556
PDF is available here.
PDF is available here.
Abstract
Follow-up ranged from 60 to 125 months (median 116 months). The mean number of Holter recordings per patient was 2.7 (range 1-11) before and 8.3 (range 2-23) after ASA (p < 0.001). Non-sustained ventricular tachycardia occurred in 14 patients before and 27 patients after ASA (23 vs. 44%, p = 0.01)....
|
PMID: 20148331
PDF is available here.
PDF is available here.
Abstract
There has been a steady decline in the number of patients treated for varicose veins. Fewer patients are undergoing surgery but are being managed more efficiently, with an increase in day cases and a reduction in total bed days. The demand for minimally invasive procedures has increased substantiall...
|
PMID: 20501021
PDF is available here.
PDF is available here.
MMW Fortschritte der Medizin (152)14 2010
Abstract
Acta Cardiologica (65)2 2010
Abstract
We achieved an improvement of the haemodynamic situation of this patient with HOCM by performing an urgent ASA....
|
PMID: 20458835
PDF is available here.
PDF is available here.
Abstract
Endoscopy is the primary diagnostic and therapeutic tool for upper gastrointestinal bleeding (UGIB). The performance of endoscopic therapy depends on findings of stigmata of recent hemorrhage (SRH). For peptic ulcer disease-the most common etiology of UGIB-endoscopic therapy is indicated for finding...
|
PMID: 20212504
PDF is available here.
PDF is available here.
Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia (145)2 2010
Abstract
Venous insufficiency of the lower-extremity is common and the prevalence increases with age. Chronic venous insufficiency has a high impact on patients' health related quality of life (HRQOL) and is associated with considerable health care costs. In addition to classical symptoms, it may result in s...
|
PMID: 20467390
PDF is available here.
PDF is available here.
The first case of takotsubo cardiomyopathy associated with sodium tetradecyl sulphate sclerotherapy.
Abstract
The present article describes the case of a 70-year-old woman who developed a classic type takotsubo cardiomyopathy after receiving cosmetic sclerotherapy for varicose veins of the legs with sodium tetradecyl sulphate (STS) injections. The patient was in her usual state of health before the injectio...
|
PMID: 20386776
PDF is available here.
PDF is available here.
Abstract
Endoscopic sclerotherapy may offer an alternative treatment for dilated gastrojejunostomy after gastric bypass. The technique described in the video is a relatively easy, safe method that may become the first line of therapy in patients who have a dilated gastrojejunostomy and have lost the feeling...
|
PMID: 20374012
PDF is available here.
PDF is available here.
Abstract
Liver International (30)3 2010
Abstract
Six-week mortality decreased from 30.4 to 17.1% [odds ratio (OR) 0.44; 0.21-0.95] with a reduction in 5-day mortality from 17.9 to 6.3% (OR 0.31; 0.11-0.86). A non-significant reduction was seen in the 5-day failure rate to control bleeding from 35.7 to 26.1%. Mortality and failure to prevent reblee...
|
PMID: 19968778
PDF is available here.
PDF is available here.
Liver International (30)3 2010
Abstract
Six-week mortality decreased from 30.4 to 17.1% [odds ratio (OR) 0.44; 0.21-0.95] with a reduction in 5-day mortality from 17.9 to 6.3% (OR 0.31; 0.11-0.86). A non-significant reduction was seen in the 5-day failure rate to control bleeding from 35.7 to 26.1%. Mortality and failure to prevent reblee...
|
PMID: 19968778
PDF is available here.
PDF is available here.
Liver International (30)3 2010
Abstract
Six-week mortality decreased from 30.4 to 17.1% [odds ratio (OR) 0.44; 0.21-0.95] with a reduction in 5-day mortality from 17.9 to 6.3% (OR 0.31; 0.11-0.86). A non-significant reduction was seen in the 5-day failure rate to control bleeding from 35.7 to 26.1%. Mortality and failure to prevent reblee...
|
PMID: 19968778
PDF is available here.
PDF is available here.
Liver International (30)3 2010
Abstract
Six-week mortality decreased from 30.4 to 17.1% [odds ratio (OR) 0.44; 0.21-0.95] with a reduction in 5-day mortality from 17.9 to 6.3% (OR 0.31; 0.11-0.86). A non-significant reduction was seen in the 5-day failure rate to control bleeding from 35.7 to 26.1%. Mortality and failure to prevent reblee...
|
PMID: 19968778
PDF is available here.
PDF is available here.
Liver International (30)3 2010
Abstract
Six-week mortality decreased from 30.4 to 17.1% [odds ratio (OR) 0.44; 0.21-0.95] with a reduction in 5-day mortality from 17.9 to 6.3% (OR 0.31; 0.11-0.86). A non-significant reduction was seen in the 5-day failure rate to control bleeding from 35.7 to 26.1%. Mortality and failure to prevent reblee...
|
PMID: 19968778
PDF is available here.
PDF is available here.
Liver International (30)3 2010
Abstract
Six-week mortality decreased from 30.4 to 17.1% [odds ratio (OR) 0.44; 0.21-0.95] with a reduction in 5-day mortality from 17.9 to 6.3% (OR 0.31; 0.11-0.86). A non-significant reduction was seen in the 5-day failure rate to control bleeding from 35.7 to 26.1%. Mortality and failure to prevent reblee...
|
PMID: 19968778
PDF is available here.
PDF is available here.
Liver International (30)3 2010
Abstract
Six-week mortality decreased from 30.4 to 17.1% [odds ratio (OR) 0.44; 0.21-0.95] with a reduction in 5-day mortality from 17.9 to 6.3% (OR 0.31; 0.11-0.86). A non-significant reduction was seen in the 5-day failure rate to control bleeding from 35.7 to 26.1%. Mortality and failure to prevent reblee...
|
PMID: 19968778
PDF is available here.
PDF is available here.
Liver International (30)3 2010
Abstract
Six-week mortality decreased from 30.4 to 17.1% [odds ratio (OR) 0.44; 0.21-0.95] with a reduction in 5-day mortality from 17.9 to 6.3% (OR 0.31; 0.11-0.86). A non-significant reduction was seen in the 5-day failure rate to control bleeding from 35.7 to 26.1%. Mortality and failure to prevent reblee...
|
PMID: 19968778
PDF is available here.
PDF is available here.
Liver International (30)3 2010
Abstract
Six-week mortality decreased from 30.4 to 17.1% [odds ratio (OR) 0.44; 0.21-0.95] with a reduction in 5-day mortality from 17.9 to 6.3% (OR 0.31; 0.11-0.86). A non-significant reduction was seen in the 5-day failure rate to control bleeding from 35.7 to 26.1%. Mortality and failure to prevent reblee...
|
PMID: 19968778
PDF is available here.
PDF is available here.
Liver International (30)3 2010
Abstract
Six-week mortality decreased from 30.4 to 17.1% [odds ratio (OR) 0.44; 0.21-0.95] with a reduction in 5-day mortality from 17.9 to 6.3% (OR 0.31; 0.11-0.86). A non-significant reduction was seen in the 5-day failure rate to control bleeding from 35.7 to 26.1%. Mortality and failure to prevent reblee...
|
PMID: 19968778
PDF is available here.
PDF is available here.
Liver International (30)3 2010
Abstract
Six-week mortality decreased from 30.4 to 17.1% [odds ratio (OR) 0.44; 0.21-0.95] with a reduction in 5-day mortality from 17.9 to 6.3% (OR 0.31; 0.11-0.86). A non-significant reduction was seen in the 5-day failure rate to control bleeding from 35.7 to 26.1%. Mortality and failure to prevent reblee...
|
PMID: 19968778
PDF is available here.
PDF is available here.
Liver International (30)3 2010
Abstract
Six-week mortality decreased from 30.4 to 17.1% [odds ratio (OR) 0.44; 0.21-0.95] with a reduction in 5-day mortality from 17.9 to 6.3% (OR 0.31; 0.11-0.86). A non-significant reduction was seen in the 5-day failure rate to control bleeding from 35.7 to 26.1%. Mortality and failure to prevent reblee...
|
PMID: 19968778
PDF is available here.
PDF is available here.
Liver International (30)3 2010
Abstract
Six-week mortality decreased from 30.4 to 17.1% [odds ratio (OR) 0.44; 0.21-0.95] with a reduction in 5-day mortality from 17.9 to 6.3% (OR 0.31; 0.11-0.86). A non-significant reduction was seen in the 5-day failure rate to control bleeding from 35.7 to 26.1%. Mortality and failure to prevent reblee...
|
PMID: 19968778
PDF is available here.
PDF is available here.
Liver International (30)3 2010
Abstract
Six-week mortality decreased from 30.4 to 17.1% [odds ratio (OR) 0.44; 0.21-0.95] with a reduction in 5-day mortality from 17.9 to 6.3% (OR 0.31; 0.11-0.86). A non-significant reduction was seen in the 5-day failure rate to control bleeding from 35.7 to 26.1%. Mortality and failure to prevent reblee...
|
PMID: 19968778
PDF is available here.
PDF is available here.
Liver International (30)3 2010
Abstract
Six-week mortality decreased from 30.4 to 17.1% [odds ratio (OR) 0.44; 0.21-0.95] with a reduction in 5-day mortality from 17.9 to 6.3% (OR 0.31; 0.11-0.86). A non-significant reduction was seen in the 5-day failure rate to control bleeding from 35.7 to 26.1%. Mortality and failure to prevent reblee...
|
PMID: 19968778
PDF is available here.
PDF is available here.
Liver International (30)3 2010
Abstract
Six-week mortality decreased from 30.4 to 17.1% [odds ratio (OR) 0.44; 0.21-0.95] with a reduction in 5-day mortality from 17.9 to 6.3% (OR 0.31; 0.11-0.86). A non-significant reduction was seen in the 5-day failure rate to control bleeding from 35.7 to 26.1%. Mortality and failure to prevent reblee...
|
PMID: 19968778
PDF is available here.
PDF is available here.
Liver International (30)3 2010
Abstract
Six-week mortality decreased from 30.4 to 17.1% [odds ratio (OR) 0.44; 0.21-0.95] with a reduction in 5-day mortality from 17.9 to 6.3% (OR 0.31; 0.11-0.86). A non-significant reduction was seen in the 5-day failure rate to control bleeding from 35.7 to 26.1%. Mortality and failure to prevent reblee...
|
PMID: 19968778
PDF is available here.
PDF is available here.
Liver International (30)3 2010
Abstract
Six-week mortality decreased from 30.4 to 17.1% [odds ratio (OR) 0.44; 0.21-0.95] with a reduction in 5-day mortality from 17.9 to 6.3% (OR 0.31; 0.11-0.86). A non-significant reduction was seen in the 5-day failure rate to control bleeding from 35.7 to 26.1%. Mortality and failure to prevent reblee...
|
PMID: 19968778
PDF is available here.
PDF is available here.
Liver International (30)3 2010
Abstract
Six-week mortality decreased from 30.4 to 17.1% [odds ratio (OR) 0.44; 0.21-0.95] with a reduction in 5-day mortality from 17.9 to 6.3% (OR 0.31; 0.11-0.86). A non-significant reduction was seen in the 5-day failure rate to control bleeding from 35.7 to 26.1%. Mortality and failure to prevent reblee...
|
PMID: 19968778
PDF is available here.
PDF is available here.
Liver International (30)3 2010
Abstract
Six-week mortality decreased from 30.4 to 17.1% [odds ratio (OR) 0.44; 0.21-0.95] with a reduction in 5-day mortality from 17.9 to 6.3% (OR 0.31; 0.11-0.86). A non-significant reduction was seen in the 5-day failure rate to control bleeding from 35.7 to 26.1%. Mortality and failure to prevent reblee...
|
PMID: 19968778
PDF is available here.
PDF is available here.
Liver International (30)3 2010
Abstract
Six-week mortality decreased from 30.4 to 17.1% [odds ratio (OR) 0.44; 0.21-0.95] with a reduction in 5-day mortality from 17.9 to 6.3% (OR 0.31; 0.11-0.86). A non-significant reduction was seen in the 5-day failure rate to control bleeding from 35.7 to 26.1%. Mortality and failure to prevent reblee...
|
PMID: 19968778
PDF is available here.
PDF is available here.
Liver International (30)3 2010
Abstract
Six-week mortality decreased from 30.4 to 17.1% [odds ratio (OR) 0.44; 0.21-0.95] with a reduction in 5-day mortality from 17.9 to 6.3% (OR 0.31; 0.11-0.86). A non-significant reduction was seen in the 5-day failure rate to control bleeding from 35.7 to 26.1%. Mortality and failure to prevent reblee...
|
PMID: 19968778
PDF is available here.
PDF is available here.
Liver International (30)3 2010
Abstract
Six-week mortality decreased from 30.4 to 17.1% [odds ratio (OR) 0.44; 0.21-0.95] with a reduction in 5-day mortality from 17.9 to 6.3% (OR 0.31; 0.11-0.86). A non-significant reduction was seen in the 5-day failure rate to control bleeding from 35.7 to 26.1%. Mortality and failure to prevent reblee...
|
PMID: 19968778
PDF is available here.
PDF is available here.
Liver International (30)3 2010
Abstract
Six-week mortality decreased from 30.4 to 17.1% [odds ratio (OR) 0.44; 0.21-0.95] with a reduction in 5-day mortality from 17.9 to 6.3% (OR 0.31; 0.11-0.86). A non-significant reduction was seen in the 5-day failure rate to control bleeding from 35.7 to 26.1%. Mortality and failure to prevent reblee...
|
PMID: 19968778
PDF is available here.
PDF is available here.
Liver International (30)3 2010
Abstract
Six-week mortality decreased from 30.4 to 17.1% [odds ratio (OR) 0.44; 0.21-0.95] with a reduction in 5-day mortality from 17.9 to 6.3% (OR 0.31; 0.11-0.86). A non-significant reduction was seen in the 5-day failure rate to control bleeding from 35.7 to 26.1%. Mortality and failure to prevent reblee...
|
PMID: 19968778
PDF is available here.
PDF is available here.
Liver International (30)3 2010
Abstract
Six-week mortality decreased from 30.4 to 17.1% [odds ratio (OR) 0.44; 0.21-0.95] with a reduction in 5-day mortality from 17.9 to 6.3% (OR 0.31; 0.11-0.86). A non-significant reduction was seen in the 5-day failure rate to control bleeding from 35.7 to 26.1%. Mortality and failure to prevent reblee...
|
PMID: 19968778
PDF is available here.
PDF is available here.
Abstract
A 5-day-old male neonate was referred to our vascular anomalies center with a large cystic submandibular mass. History and physical examination and ultrasonographic results indicated the diagnosis to be macrocystic lymphatic malformation. Consequently, the child was treated with sclerotherapy and su...
|
PMID: 20186073
PDF is available here.
PDF is available here.
American Journal of Nursing (110)2 2010
Abstract
Esophageal varices occur in about half of all people with alcoholic cirrhosis. About one-third of these will experience variceal hemorrhage, a life-threatening event. This article describes alcoholic cirrhosis and its complications, discusses the etiology of esophageal varices and the risk factors f...
|
PMID: 20107398
PDF is available here.
PDF is available here.
Abstract
A 75-year-old man with portal hypertension was referred to our institution because he suddenly began to pass a large amount of tarry stool. Arterial portography and computed tomography (CT) during arterial portography via the superior mesenteric artery, using a unified 64-slice multidetector row CT...
|
PMID: 20182854
PDF is available here.
PDF is available here.
American Surgeon (76)2 2010
Abstract
This review encompasses the basic pathophysiology, diagnosis, and current therapies for superficial venous insufficiency.
|
PMID: 20336886
PDF is available here.
PDF is available here.
Vascular Medicine (15)1 2010
Abstract
We reviewed medical records of a consecutive cohort of patients who underwent EFS over a 2-year period. The primary outcome measure was obliteration of VVs. The secondary outcome measures were symptomatic improvement, ulcer healing, recurrence, and adverse events. A total of 166 patients (217 legs)...
|
PMID: 19797263
PDF is available here.
PDF is available here.
Vascular Medicine (15)1 2010
Abstract
We reviewed medical records of a consecutive cohort of patients who underwent EFS over a 2-year period. The primary outcome measure was obliteration of VVs. The secondary outcome measures were symptomatic improvement, ulcer healing, recurrence, and adverse events. A total of 166 patients (217 legs)...
|
PMID: 19797263
PDF is available here.
PDF is available here.
Vascular Medicine (15)1 2010
Abstract
We reviewed medical records of a consecutive cohort of patients who underwent EFS over a 2-year period. The primary outcome measure was obliteration of VVs. The secondary outcome measures were symptomatic improvement, ulcer healing, recurrence, and adverse events. A total of 166 patients (217 legs)...
|
PMID: 19797263
PDF is available here.
PDF is available here.